Immuneering Reports Positive Initial Data For IMM-1-104 In Phase 2a Pancreatic Cancer Trial;stock Up
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Immuneering Corp. (IMRX) announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial.
:max_bytes(150000):strip_icc():format(jpeg)/Mediation-56a260535f9b58b7d0c975bb.jpg "How Divorce Impacts Your Credit Score")
:max_bytes(150000):strip_icc():format(jpeg)/bankers-9e9fc2e9cdb8479eb443b9783b436848.jpg "What Is a High-Yield Savings Account?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1556517575-d380026162654742ad89f5a8ef134d40.jpg "The Main Types of Annuities Made Easy")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1500340373-9a9166e04b064f1d926066341a5e27f8.jpg "Next Fed Meeting: When It Is In September and What To Expect")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1371757399-3329dac503a74576a455122fc2b08246.jpg "<div>9 Major Medicare Changes for 2025 and How They'll Impact Your Coverage</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")